Navigating Non-Product Software Validation in GxP Environments

1. Introduction

When life sciences organizations talk about software validation, the conversation always gravitates toward product software, embedded device firmware, or clinical trial software that touches the regulated product directly.

There is an equally important category of GxP software that underpins every regulated operation: non-product software. It includes laboratory information management systems (LIMS), quality management systems (QMS), document management platforms, training systems, and AI-driven analytical tools. Even without being part of the product itself, this software must still be validated.

‍

‍

2. What Is Non-Product Software?

Non-product software is any software used in a GxP-regulated environment that does not become part of the product and is not embedded in a medical device. Despite this distinction, it directly influences product quality, patient safety, and data integrity, which is precisely why it falls within the scope of regulatory oversight.

Examples  include:

• Quality Management Systems (QMS): CAPA management, deviation tracking, document control, training management, audit management platforms
• Laboratory Systems: LIMS, electronic lab notebooks (ELN), chromatography data systems (CDS)
• Manufacturing Systems: MES, SCADA, building management systems, batch record systems, ERP modules governing GxP operations
• Regulatory & Submission Support Tools: AI/ML models used to analyze manufacturing data, generate statistical summaries, or support regulatory submissions
• Infrastructure & Supporting Software: Backup and restore systems, access management platforms, audit trail repositories, archival systems

3. Overlapping Common Expectations

Risk-Based Validation & Classification

• FDA CSA replaces the old "validate everything to the same standard" model with a critical-thinking, risk-driven approach.
• FDA AI Guidance for Drugs and Biologics classifies AI models by the influence their output has on regulatory or manufacturing decisions, with higher influence requiring greater rigor in credibility assessment.
• GAMP5 uses its well-established software category framework to stratify validation effort by system complexity and criticality.
• ISO 13485 Clause 7.5.6 requires that software used in production and service provision be validated prior to use, with the extent of validation activities proportionate to the risk associated with the software's use.

Risk assessment for a non-product software system must evaluate the consequences of failure across three dimensions: patient safety impact (direct or indirect), data integrity impact, and product quality impact. A batch release system that could allow an out-of-specification product to reach a patient demands far more rigorous assurance than a training record management system, even though neither is a product in itself. The risk assessment output must be documented and must explicitly justify the scope of validation activities selected.

For AI-driven non-product software, risk assessment must additionally consider the nature of the model's output (does it inform a human decision, or does it automate one?), the consequences of a wrong prediction, and the degree to which model drift could introduce systematic errors before detection.

Requirements Management & Full Lifecycle Traceability

• GAMP5 mandates a User Requirements Specification (URS) as the foundation of the validation lifecycle and requires traceability matrices linking requirements to test evidence.
• ISO 13485 Clause 7.3 requires documented design inputs and outputs with demonstrable traceability between them.
• FDA CSA requires that the intended use of the software be defined and that testing activities be traceable to that intended use, even when using exploratory rather than scripted methods.
• FDA AI Guidance for Drugs and Biologics requires that AI model validation evidence be traceable to the model's defined intended use and performance specifications.

Every system in scope, from LIMS to your AI-powered process monitoring platform, must have a documented URS that defines what the system is required to do, and a validation package that demonstrates those requirements were met. For AI systems, this includes documented performance specifications (accuracy, precision, recall, confidence thresholds) against which model testing results can be assessed.

Change Control & Impact Assessment

• FDA CSA requires that changes be assessed for their potential impact on system performance and data integrity, with reassurance activities scaled to the risk of the change.
• GAMP5 provides detailed guidance on change impact categories and the corresponding re-validation activities required for each.
• ISO 13485 Clause 7.3.9 requires that changes to software be controlled and re-validated where necessary to ensure continued conformity.
• FDA AI Guidance for Drugs and Biologics specifically addresses AI model retraining and version updates as change events requiring documented impact assessment and re-validation.

Change control SOP must be written with modern software deployment patterns in mind, not just traditional waterfall patch management. Cloud-hosted systems may update continuously. AI models may be retrained on new data without an obvious version increment. The change control process must define what constitutes a triggering change event for each system type, what impact assessment criteria apply, and what re-testing is required before the changed system is returned to production.

For AI-driven non-product software, a particularly important question is: at what point does accumulated model drift constitute a change requiring formal re-validation? All four frameworks direct you to your risk assessment to answer that question.

Audit Trail, Data Integrity & Electronic Records

Every GxP electronic record created, modified, or deleted by a non-product software system must be captured in a secure, computer-generated audit trail. Audit trails must be archived with their associated records for the full retention period.

• FDA CSA frames audit trail capability as a fundamental data integrity control, particularly for systems supporting GxP decisions.
• FDA AI Guidance for Drugs and Biologics extends this to model inputs and outputs; regulators expect to be able to trace which version of a model generated which output, under what conditions, and who reviewed it.
• GAMP5 and ISO 13485 both treat audit trail and data integrity controls as non-negotiable elements of any GxP computerized system.

For traditional non-product software, audit trail requirements are well understood. The emerging challenge is AI-driven systems, where the "record" may be a model prediction, an anomaly flag, or an automatically generated report. These outputs are GxP records if they influence GxP decisions, and they must be treated as such, versioned, auditable, and retained.

Data integrity program for non-product software must explicitly address: which fields and records require audit trail coverage, how audit trails are reviewed, by whom, and how often, and how audit trail data is archived and protected through the retention period.

Testing Strategy Proportionate to Risk

• FDA CSA introduced unscripted, exploratory testing as a formally accepted assurance method, recognizing that critical thinking by qualified testers often uncovers more meaningful defects than scripted regression testing.
• GAMP5's second edition similarly acknowledges agile, exploratory, and risk-based testing approaches alongside the traditional V-model.
• ISO 13485 requires that validation activities demonstrate that software meets its specified requirements under representative conditions.
• FDA AI Guidance for Drugs and Biologics requires that AI models be tested not just on aggregate performance metrics but on clinically or operationally relevant subpopulations, failure modes, and edge cases.

Testing strategy for non-product software must be documented, justified by risk, and evidence-based. For conventional systems, this means IQ/OQ/PQ protocols with clear acceptance criteria. For AI-driven systems, this requires a statistical validation plan that addresses model performance across relevant data distributions, boundary conditions, and failure scenarios.

Critically, your testing tools are themselves subject to validation. Automated testing frameworks, test harnesses, and data generation scripts used in non-product software validation must be qualified for their intended purpose, a requirement explicitly stated in both GAMP5 and the GxP validation principles underpinning CSA.

Document Lifecycle Management & Version Control

‍

An undocumented or informally documented validation is not a validation. Every non-product software system must have a controlled, complete, and current validation package. For AI systems specifically, this package must include documentation of training data sources and quality, model architecture decisions, hyperparameter selection rationale, performance validation results, and the human review process applied to model outputs.

Access Control, User Roles & Permissions

• GAMP5 and ISO 13485 require that user access levels be defined, implemented, and verified as part of system validation.
• FDA CSA requires that access controls support data integrity; unauthorized access is a data integrity risk, not merely a security concern.
• FDA AI Guidance for Drugs and Biologics implicitly extends this to AI model governance: who can promote a model to production, override its output, or initiate a retraining cycle must be governed by defined roles and access controls.

The access control framework for non-product software must be role-based, documented, and auditable. Critically, for AI-driven systems, your access control design must address the full model governance workflow, not just end-user access. Data scientists, model owners, QA reviewers, and release approvers each require distinct, controlled access rights, and those rights must be documented and periodically reviewed.

Incident Management, CAPA & Deviation Handling

• ISO 13485 Clause 8.5 mandates CAPA processes for quality system failures, including software-related deviations.
• GAMP5 requires incident management as part of the operational phase of the validated system lifecycle.
• FDA CSA requires that software failures be investigated and remediated as part of the site quality system.
• FDA AI Guidance for Drugs and Biologics recognizes that AI model failures may have complex, non-deterministic root causes requiring investigation processes sophisticated enough to distinguish random variation from systematic model failure.

Incident management SOP must explicitly address software and AI system incidents, not just process deviations. For AI-driven non-product software, this means your quality system must be capable of investigating incidents where the root cause may be a distributional shift in input data, model drift, or unexpected interactions between the AI system and adjacent GxP systems, failure modes that are qualitatively different from traditional software defects.

Vendor & Supplier Qualification

‍

Supplier qualification program must be comprehensive, risk-prioritized, and regularly maintained. For COTS systems, vendor documentation should be reviewed against your URS to determine what gaps require additional testing. For AI platform vendors, qualification must extend to data governance practices, model versioning, and the vendor's own validation methodology. Service Level Agreements must address disaster recovery, data ownership, and the vendor's obligations when software updates are released.

Periodic Review & Continued State of Control

• ISO 13485 requires ongoing monitoring and measurement of processes, including software-supported processes, to ensure continued effectiveness.
• GAMP5 defines periodic review as a formal lifecycle activity, with documented outcomes and remediation plans for systems found to be out of control.
• FDA CSA requires that the continued suitability of assurance activities be assessed as systems and their risk profiles evolve.
• FDA AI Guidance for Drugs and Biologics addresses model performance monitoring as an ongoing requirement; periodic review for AI systems must include statistical performance trending to detect drift before it reaches a clinically or operationally significant level.

Periodic review must define review frequency by system risk category, the data and metrics reviewed, the criteria for determining a system is in a state of control, and the escalation path when it is not. For AI-driven non-product software, periodic review must include quantitative model performance metrics alongside the traditional infrastructure and change history review.

4. Conclusion

The four frameworks examined here, FDA CSA, the FDA AI Guidance for Drugs and Biologics, GAMP5, and ISO 13485, converge on the same core expectations: risk-based classification, requirements traceability, change control, data integrity, and periodic review. Organizations do not need four compliance programs. They need one program built on this shared architecture, with extensions where a specific framework imposes additional requirements. The goal is not to collect validation documents. The goal is to ensure that every non-product software system in your GxP environment reliably does what it is supposed to do, that you can prove it, and that you will know when it stops.

‍

‍